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The abnormal expression of microRNAs (miRNAs) is implicated in various human diseases, including cancers. Accordingly,
miRNA expressions have been examined in many cancer tissues and blood, but there have been few studies examining
smear samples from bone marrow (BM) or peripheral blood. Here we successfully isolated small RNAs from BM smears
using a mirVana miRNA Isolation Kit with our original modifications. The isolated small RNAs were then used to measure
the levels of representative miRNAs such as miR-155, let-7a, and U6 via real-time PCR with a specific TaqMan probe,
although peaks for the ribosomal RNAs (18S, and 28S) were not identified. The PCR curves of the miRNAs were
indistinguishable from those from BM living cells from the same donor. Finally, our method for BM smears identified
numerous abnormally altered miRNAs (significantly decreased, 39 miRNAs; significantly increased, 27 miRNAs) in follicular
lymphomas (FL) compared with normal donors via TaqMan real-time PCR miRNA array. The array indicated that miR-451
showed the greatest decrease in FL (a 345-fold decrease), while miR-338-5p showed the greatest increase in FL (172-fold)
relative to normal donors. The miRNAs identified by our study might serve as markers to predict the invasion of FL cells
into BM without biopsy. Furthermore, our method will provide a new avenue for the analysis of miRNAs in BM smear
samples from various hematologic diseases.
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MicroRNAs (miRNAs), which are short non-coding single-
stranded RNAs of 18–24 mer in length, negatively regulate
the target gene expression at the post-transcriptional stage
(Bartel 2004; Ambros 2004). miRNAs act to inhibit protein
translation or degrade transcripts of the target gene (Bartel
2009). Many studies have demonstrated that abnormal ex-
pression of miRNAs is implicated in a variety of human dis-
eases, including cancers (Calin and Croce 2006; Takei et al.
2011). Accordingly, the levels of various miRNAs have been
measured in body fluids such as blood (serum or plasma),
urine, cerebrospinal fluid, and ascites of patients with can-
cer (Cortez et al. 2011; Etheridge et al. 2011). Based on
these measurements, some of the circulating miRNAs have* Correspondence: takei@med.nagoya-u.ac.jp
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in any medium, provided the original work is pbeen regarded as beneficial biomarkers to efficiently diag-
nose cancers. Recent reports have indicated that circulating
miRNAs are quite stable even in an extracellular ribonucle-
ase(s)-ubiquitous environment, such as in blood or other
body fluids (Grasedieck et al. 2012), since most of the miR-
NAs there are packaged into exosomes or microvesicles
(Hunter et al. 2008; Skog et al. 2008), into lipoprotein parti-
cles with high density (Vickers et al. 2011), or into apop-
totic bodies (Zernecke et al. 2009). These molecular
packaging mechanisms protect the miRNAs in body fluids
from degradation, and thus, particularly in hematological
cancers, some blood-circulating miRNAs can become ex-
cellent biomarkers to directly mirror the origin of cancers
(Grasedieck et al. 2013).
Microscopic bone marrow (BM) examination is
performed to diagnose many blood diseases, including
leukemia, lymphoma, and multiple myeloma (Ryan 2010).
The BM generates the cells in blood, including red blood
cells, white blood cells, and platelets. BM samples are or-
dinarily acquired by aspiration or trephine biopsy, andOpen Access article distributed under the terms of the Creative Commons
g/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction
roperly credited.
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BM. Like peripheral blood smears, the BM samples are
often stored as smears at room temperature (Miura et al.
2011). These smears also can be transported anywhere
while remaining at room temperature, and thus are con-
venient for use in diagnoses.
Here we successfully isolated the small RNA fractions
from BM smears, and showed that these fractions could
be used to quantitate miRNAs via a typical real-time
PCR method. In addition, we applied the small RNA
fractions to a TaqMan real-time PCR miRNA array, and
thereby identified many miRNAs whose levels were sig-
nificantly altered in follicular lymphoma (FL), compared
with the BM smears from normal donors. To our know-
ledge, this is the first report in which disease-associated
miRNAs were identified from BM smears.Materials and methods
Patients
In the present study, we studied bone marrow (BM) sam-
ples from patients with follicular lymphoma (FL) of B cell-
type who were diagnosed at Hiroshima University Hospital,
and from normal donors used as a control. All patients pro-
vided informed consent according to the Declaration of
Helsinki. The study protocol was approved by the Institu-
tional Review Board of Hiroshima University Hospital. All
of the FL patients studied in the article were classified on
Stage IV, and in all cases, the infiltration of the malignant
cells into BM was observed (Table 1). The extent of BM in-
filtration of the malignant cells via flow cytometric analysis
(Mihara et al. 2010) was also given in Table 1. For normal
donors, we used the BM specimens from slight pancyto-
penia patients. On admission, although they were suspected
to be aplastic anemia, we found they showed pancytopenia
by individual differences according to our clinical examina-
tions. Their pancytopenia was not progressive. Their BM
was qualitatively and quantitatively normal without filtra-





The extent of BM infiltration
by lymphoma cells
Normal 1 22 Male - 0%
Normal 2 43 Male - 0%
Normal 3 29 Male - 0%
FL Patient 1 61 Male IVA 46% A
FL Patient 2 66 Male IVA 54% A
FL Patient 3 72 Male IVA 49%
FL Patient 4 68 Male IVA 38%
FL Patient 5 59 Male IVA 42% S
*Date of BM sampling and preparation of BM smears.Preparation of BM smears
BM samples were obtained via an aspiration and biopsy.
BM smears were made by placing a drop of BM on a glass
slide by the previously described method (Ryan 2010).
Table 1 provides a list of BM smears from patients with FL
(B cell type) and normal donors, along with the date of
sampling and preparation of smears. We also showed each
age of the BM smears (a stock time from the preparation
up to use). All of the BM smears without fixation were kept
at room temperature until use.Isolation of small RNAs from BM smears
Isolation of small RNAs, including miRNAs from BM
smears, was performed using a mirVana miRNA Isola-
tion Kit, or an RNAqueous-Micro Kit (a protocol for
laser-captured microdissection samples) (Life Tech-
nologies Japan, Tokyo, Japan). We modified the manu-
facturer’s protocol for adequate isolation from BM
smears.
For the isolation using the mirVana miRNA Isolation
Kit, one BM smear slide was placed on a clean 100 mm
dish, and lysis/binding buffer (300 μl) from the kit was
dropped on the slide. Using a clean cell scraper and a
pipette with a 1-ml tip, the dried smear component on
the slide could be resolved but with high viscosity. The
lysate from two BM smear slides was collected into a 2-
ml tube, and the liquid volume was measured. A one-
tenth volume (miRNA Homogenate Additive) of the
lysate was added, and then the solution was mixed and
incubated on ice for 10 minutes. An equal volume (acid-
phenol chloroform) of the lysate was added, and then
the solution was mixed with a vortex for 5 minutes, and
centrifuged (10,000 rpm for 5 minutes). This extraction
step can be repeated two or three times; the repetition
was particularly effective for the already-stained BM
smears. The water-phase was collected, and its liquid
volume measured. Ethanol (a 1.25-times volume of the
water-phase) was added, and the solution was mixed.pe) in the study
Date* Age of the BM smears from the preparation up to use
(Stock time at room temperature)
Jul 9, 2008 2 years and 10 months
Jul 19, 2006 4 years and 10 months
Apr 16, 2008 3 years and 1 month
ug 11, 2006 4 years and 9 months
ug 29, 2008 2 years and 9 months
Apr 5, 2006 5 years and 1 month
Sep 5, 2008 2 years and 10 months
ep 15, 2006 4 years and 10 months
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ridge and centrifuged (the flow-through liquid was dis-
carded). After washing the filter cartridge with Wash
Solution 1 and 2/3, 100 μl of an elution solution heated
at 95°C was added to the column, and 5 minutes later
the desired solution was recovered by centrifugation.
For the isolation using the RNAqueous-Micro Kit, Lysis
Solution (300 μl) from the kit was added onto one BM
smear slide, and scraped using a clean cell scraper. For an-
other BM smear slide, we repeated the procedure. The lys-
ate (total 600 μl from two BM smear slides) was incubated
at 42°C for 30 minutes, and then the supernatant by centri-
fugation was collected. Fifteen μl of LCM Additive from
the kit was added to the supernatant (500 μl) and the solu-
tion was vigorously mixed, and then ethanol (1.25-times
volume of the supernatant) was added with mixing. All of
the mixture was applied onto a micro-filter cartridge and
centrifuged (the flow-through liquid was discarded). After
washing the cartridge with Wash Solution 1 and 2/3, 10 μl
of an elution solution heated at 95°C was added to the col-
umn, and 5 minutes later the desired solution was recov-
ered. The elution was repeated using another 10 μl of
elution solution. Finally, 20 μl of the eluted solution was
obtained.
Our modified methods are just matched for two BM
smear slides (e.g., each liquid volume and handling, and
column and tube size). The isolated small RNAs from two
BM slides are enough to carry out several examinations
such as qPCR, and array analysis. The critical points for the
effective isolation are on ‘acid-phenol chloroform step’ to
prevent and regulate high viscosity, which is peculiar to BM
smears. The repetition of the step reduced their viscosity.
The RNA concentration of the eluted solution was de-
termined by a NanoDrop ND-1000 spectrophotometer
(Invitrogen), and its quality was examined using an
Agilent 2100 Bioanalyzer (Agilent Technologies).
Quantitative reverse transcription-PCR (qRT-PCR) for
miRNA
Small RNAs isolated from BM smears were subjected to
qRT-PCR for miRNAs such as U6, miR-155, and let-7a.
Each RNA sample (10 ng) was reverse-transcribed using a
TaqMan MicroRNA RT Kit and TaqMan MicroRNA Assay
(Applied Biosystems), and the obtained cDNA was analyzed
using specific TaqMan probes (U6, Assay ID 001973; miR-
155, Assay ID 000479; and let-7a Assay ID 000377) and
TaqMan Universal PCR Master Mix as described previously
(Takei et al. 2011). All of the reactions and analyses
were performed using a StepOne Real-Time PCR System
(Applied Biosystems).
TaqMan real-time PCR miRNA array
The RNA samples shown in Table 2 (from five patients
with FL and three normal donors) were subjected to aTaqMan Array MicroRNA Card (version 2.0 for humans;
Applied Biosystems). This real-time PCR miRNA array al-
lows the simultaneous quantitation of up to 667 human
miRNAs in a sample. For the RT reaction, we used the
Megaplex RT Primers Pool for humans (Applied Biosys-
tems), which is suitable for comprehensive miRNA meas-
urement. Each RNA sample (500 ng) was thus subjected to
both Megaplex RT reactions and subsequent PCR reactions
according to the manufacturer’s protocol. All of the reac-
tions were run on the ABI PRISM 7900 System (Applied
Biosystems). Raw data were analyzed by using DataAssist
software (version 3.0; Applied Biosystems). For the un-
detectable results on PCR, we defined the CT value as 40.
The expressions of all the miRNAs were calculated relative
to that of U6 small nuclear RNA (RNU6B) by the compara-
tive ΔCt method (Livak and Schmittgen 2001).
Statistical analysis
Statistical analysis on TaqMan real-time PCR miRNA
array was performed using the Mann-Whitney U test.
Probability values were shown in each table and the
values less than 0.01 (1 × 10-2) were considered to indi-
cate significant differences.
Results
Successful isolation of small RNAs from BM smears
We used two isolation kits with modifications to obtain
small RNAs from BM smears: a mirVana miRNA Isolation
Kit and an RNAqueous Kit. Both kits revealed very similar
ferrograms (Agilent 2100 Bioanalyzer) of isolated RNAs:
only one peak of small RNAs (under 500 nt) was observed,
but no peaks of ribosomal RNA (18S and 28S) were seen
(Figure 1A). We determined the RNA concentration with a
NanoDrop ND-1000 spectrophotometer, and the ratio of
A260/A280 showed a satisfactory value (Figure 1B). The
RNA integrity number (RIN) was 2.5. There were no differ-
ences in results between the two kits. These findings sug-
gested that, in the BM smears, the RNAs of larger size
(over 500 nt) were completely degraded, whereas the
smaller RNAs remained potentially reactive.
Successful quantitative PCR analysis for miRNAs in small
RNA fractions from BM smears
Using the isolated small RNA fractions, we performed
quantitative PCR analysis for three representative miR-
NAs (U6, let-7a, and miR-155) with TaqMan probes. All
three miRNAs were successfully amplified (Figure 1C),
demonstrating that the miRNAs from BM smears can be
quantified by PCR. The PCR curves were not notably
different between the two kits, suggesting both small
RNAs were equally functional. We decided to use the
mirVana miRNA Isolation Kit for further study due to
its simplicity.
Table 2 Quality check of the isolated RNAs from normal donors and FL patients according to our proposed method
ID RNA concentration (ng/μl) Total yield (μg) A260/A280 RIN*
Normal 1 27.6 2.8 1.81 2.5
Normal 2 28.2 2.8 1.87 2.6
Normal 3 33.8 3.4 1.91 2.6
FL Patient 1 24.6 2.5 1.74 2.6
FL Patient 2 28.0 2.8 1.84 2.5
FL Patient 3 14.4 1.4 1.88 2.4
FL Patient 4 17.9 1.8 1.82 2.6
FL Patient 5 22.5 2.3 1.80 2.5
*RNA integrity number.
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We obtained living cells of BM from the same donor who
provided the BM smears. Figure 2A shows a ferrogram of
BM living cells isolated by the mirVana miRNA Isolation
Kit. Peaks of 18S and 28S were observed, and the RNA


























*, A protocol for laser-captured microdissection
**, Elution volume=100 μl
***, Elution volume=20 μl
****, RNA Integrity Number
Figure 1 Successful isolation of small RNAs from BM smears and func
the isolated RNA from BM smears. Left, mirVana miRNA Isolation Kit; and rig
RNAs. RIN, RNA integrity number. C, Functional qRT-PCR for miRNAs (U6, le(Figure 2B). Of course, the three miRNAs described above
could be detected and quantified via the PCR method
(Figure 2C). In view of the quantitative PCR analysis for the
three miRNAs, the small RNA fraction from the BM


























tional quantitative PCR analysis for the miRNAs. A, Ferrograms of
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*, This bone marrow living cells are derived from the same patient of Fig. 1.
**, Eluted volume was 100 μl. 






          living cells*
A260/A280
1.83
Figure 2 Small RNAs from BM living cells gave almost identical results. A, A ferrogram of the isolated RNA from BM living cells. nt,
nucleotide. B, Quality of the isolated small RNAs. RIN, RNA integrity number. C, Functional qRT-PCR for miRNAs (U6, let-7a, and miR-155).
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quantitative PCR of the miRNAs
We considered that our procedure would be more con-
venient if it could be applied to the already-stained
smears, since the BM smears are often stained with per-
oxidase or May-Giemsa stain. Therefore, we isolated the
small RNAs in the following three BM smears (un-
stained, PO-stained, and MG-stained) from the same
donor. As shown in Figure 3A, the RNA quality (A260/
A280) was not affected by the staining. The RIN was
around 2.5 (Figure 3A). The quantitative PCR analysis
for the three miRNAs (U6, let-7a, and miR-155) revealed
that all three of the isolated small RNAs could be suc-
cessfully used (Figure 3B-D). These results showed thatsmall RNAs from BM smears, whether unstained or
already-stained, can be used to quantitate miRNAs.
miRNAs with significant abnormal alterations were found
in the smears from the patients with FL compared with
normal donors
Using our established isolation procedure for small
RNAs, we quantitated the miRNA levels in BM smears
from five FL patients and three normal donors. Tables 1
and 2 summarize the characteristics for each subject.
The isolated small RNAs were subjected to the TaqMan
real-time PCR miRNA array, and the results showed that
the levels of many miRNAs were significantly different
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PO-stained 19.9* 1.99 1.87 2.6
Figure 3 Small RNAs from the already-stained BM smears could still be successfully used in qRT-PCR for miRNAs (U6, let-7a, and miR-
155). A, RNA quality, B, unstained; C, stained (PO); and D, stained (MG). PO, peroxidase staining; and MG, May-Giemsa staining.
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The 20 miRNAs with the greatest increases and decreases
are shown; the other significantly altered miRNAs are
shown in Additional file 1. As shown in Table 3, the results
of our analysis of abnormally expressed miRNAs in FL pa-
tients were surprising, since the differences between the ab-
normal miRNA expression levels and the expressions in
normal donors were much greater than expected. For ex-
ample, miR-451, the miRNA exhibiting the greatest de-
crease, was reduced by 345-fold in FL patients relative to
normal donors; while miR-338-5p, the most-increased
miRNA, showed a 172-fold increase. Among the decreased
miRNAs (Table 3), miR-451 (Rank 1), miR-144 (Rank 2),
and miR-144* (Rank 15) were clustered; and miR-452
(Rank 3) and miR-224 (Rank 5) were also clustered. With
respect to the increased miRNAs, the three miRNAs (miR-24-2*, miR-23a, and miR-27a*) were registered in miRBase
(Release 20, June 2013) as clustered miRNAs (Table 3).
These results showed that abnormally expressed miRNAs
often showed a tendency to gather and move together in
groups (clusters), suggesting that there are some weak
chromosomal region(s) in FL patients, such as chromo-
somal locations 17q11.2, Xq28, and 19p13.13 (Table 3).
Discussion
Smear samples are easy to store and to transport at
room temperature. Thus, they are handy to use. They
provide much information for the diagnosis of many dis-
eases, including hematologic diseases, and particularly
hematological malignancies. In the present study, we suc-
cessfully isolated small RNAs from BM smears of FL pa-
tients, and according to TaqMan real-time PCR miRNA
Table 3 Significantly altered miRNAs (Top 20) in the patients with FL, compared with normal donors
Rank miRNA Clustered miRNAs Fold change Probability values* Chromosomal location
Decreased
1 miR-451 a -345 2.6 × 10-6 17q11.2
2 miR-144 a -179 1.6 × 10-5 17q11.2
3 miR-452 b -140 1.7 × 10-5 Xq28
4 miR-494 -107 5.1 × 10-5 14q32.31
5 miR-224 b -89.5 6.7 × 10-5 Xq28
6 miR-486-3p -86.0 5.2 × 10-5 8p11.21
7 miR-483-3p -75.1 4.5 × 10-5 11p15.5
8 miR-190a -67.4 1.8 × 10-4 15q22.2
9 miR-10b* -62.6 2.3 × 10-4 2q31.1
10 miR-939 -60.3 7.1 × 10-5 8q24.3
11 miR-1248 -55.8 1.1 × 10-4 3q27.3
12 miR-302b -52.7 2.4 × 10-4 4q25
13 miR-1303 -50.9 5.1 × 10-5 5q33.2
14 miR-486-5p -48.6 3.3 × 10-4 8p11.21
15 miR-144* a -45.5 2.2 × 10-5 17q11.2
16 miR-511 -41.2 3.4 × 10-5 10p12.33
17 miR-203a -40.4 5.4 × 10-5 14q32.33
18 miR-202 -38.0 6.2 × 10-4 10q26.3
19 miR-204 -35.2 5.0 × 10-5 9q21.12
20 miR-182 -32.3 7.4 × 10-4 7q32.2
Increased
1 miR-338-5p 172 3.2 × 10-5 17q25.3
2 miR-200a 75.9 6.4 × 10-5 1p36.33
3 miR-24-2* c 45.4 6.0 × 10-5 19p13.13
4 miR-23a c 41.2 4.9 × 10-5 19p13.13
5 miR-31 37.0 3.5 × 10-4 9p21.3
6 miR-639 35.9 5.9 × 10-5 19p13.12
7 miR-27a* c 29.3 6.2 × 10-4 19p13.13
8 miR-29a* 26.9 5.8 × 10-4 7q32.3
9 miR-146b-3p 25.5 3.9 × 10-5 10q24.32
10 miR-374a* 23.0 3.2 × 10-4 Xq13.2
11 miR-766 21.1 5.3 × 10-4 Xq24
12 miR-1271 20.2 6.0 × 10-5 5q35.2
13 miR-181a-2* 19.3 5.4 × 10-4 9q33.3
14 miR-616 15.6 7.5 × 10-5 12q13.3
15 miR-7* 12.0 5.1 × 10-5 9q21.32
16 miR-30d* 10.3 8.8 × 10-4 8q24.22
17 miR-885-5p 10.2 2.9 × 10-4 3p25.3
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Table 3 Significantly altered miRNAs (Top 20) in the patients with FL, compared with normal donors (Continued)
18 miR-941 8.35 5.2 × 10-4 20q13.33
19 miR-1208 6.69 2.3 × 10-4 8q24.21
20 miR-26b* 6.57 2.0 × 10-4 2q35
a, b, and c: miRNAs clustered together in groups.
The same letter (a, b, or c) represents the miRNAs clustered in the same group.
*,Probability values by Mann-Whitney U test (VS normal donors) were shown.
Probability values less than 0.01 (1 × 10-2) were considered to indicate significant differences.
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were significantly altered in the patients compared with
normal donors (Table 3 and Additional file 1). To our
knowledge, this is the first report in which disease-
associated miRNAs were identified from BM smears.
The abnormal expression of miRNAs has been impli-
cated in a variety of human diseases, including cancers. Cir-
culating miRNAs have thus received much attention for
their potential as stable blood-based biomarkers for detect-
ing cancers Grasedieck et al. 2013; Mitchell et al. 2008;
Hessvik et al. 2013). Circulating miRNAs in body fluids are
much stable due to their packaging into exosomes, micro-
vesicles, or lipoproteins (Hunter et al. 2008; Skog et al.
2008; Vickers et al. 2011). Regarding hematologic malig-
nancies, the use of miRNA profiling for cancer biopsy sam-
ples from patients with FL has been reported (Roehle et al.
2008; Lawrie et al. 2009; Wang et al. 2012; Leich et al.
2011). However, circulating miRNAs in the BM of FL pa-
tients, especially in their BM smears, have not yet been re-
ported. Based on a comparison of the previous reports (FL
tissues; refs. Roehle et al. 2008; Lawrie et al. 2009; Wang
et al. 2012; Leich et al. 2011) and our present report (BM
smears from FL), the miRNAs that showed significant alter-
ations in both cancer tissues and BM smears from FL com-
pared with normal donors were as follows: the significantly
decreased common miRNAs were miR-202 (Rank 18), and
miR-139-5p (Rank 37); and the significantly increased miR-
NAs were miR-338-5p (Rank 1), miR-9 (Rank 21), and
miR-330-3p (Rank 24). All of the other altered miRNAs in
BM smears from FL patients, as shown in Table 3 and Add-
itional file 1, were newly identified in our study.
FL is regarded as one of the malignant lymphomas
that actively invade into BM; however, we currently have
no ideas for appropriate marker(s) to detect such inva-
sion without biopsy. Further, the mechanism(s) by which
FL cells so readily invade into BM remains poorly under-
stood. The results of the present study suggest that the
measurement of some miRNA expression level(s) in BM
smears can be used to correctively predict and diagnose
FL without lymph node biopsy, although much investi-
gation remains to be performed prior to the actual appli-
cation for simple diagnosis of FL.
The stability of miRNAs in formalin-fixed paraffin-
embedded (FFPE) tissues has already been reported, and
thus many studies have shown that archived FFPE tissuesamples can be used for PCR-based miRNA analysis
(Li et al. 2007; Xi et al. 2007; Doleshal et al. 2008; Kolbert
et al. 2013), or next-generation sequencing (Kelly et al.
2013; Meng et al. 2013). Here, the RIN of RNA fractions
isolated from FFPE tissues was generally low (approxi-
mately 2.4–2.6), indicating that the RNAs were heavily
fragmented. This, in turn, means that the small RNAs
isolated from BM smears and FFPE tissues are quite
similar to each other, and they might be suitable for
miRNA quantitation rather than gene expression analysis.
Indeed, our BM smears are not suitable for determining
mRNA expression levels via quantitative RT-PCR (data
not shown).
Conclusion
Our isolation method provides a new avenue for the
analysis of miRNAs in BM smear samples from patients
with various diseases, particularly blood malignancies.
Using this method, numerous miRNAs with potential as
diagnostic markers in BM may be identified in the near
future.
Additional file
Additional file 1: Significantly decreased and increased miRNAs
(below Rank 21) in FL patients, compared with normal donors.
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